CBD Life Sciences Inc. (CBDL)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CBD Life Sciences Inc. (CBDL) trades at $0.00 with AI Score 41/100 (Grade C). CBD Life Sciences Inc. develops and markets cannabidiol (CBD) based organic products, including hemp drops, massage oils, and pain relief creams. Market cap: $375,394, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for CBDL: CBDL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CBDL against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CBDL: the 1 perspectives are evenly split.
How is this calculated? →CBD Life Sciences Inc. (CBDL) Healthcare & Pipeline Overview
CBD Life Sciences Inc. is a small healthcare company focused on developing and marketing cannabidiol (CBD) based organic products, including hemp drops, massage oils, and pet products. Operating in the specialty and generic drug manufacturing industry, the company faces challenges with profitability and market competition.
What Is the Investment Thesis for CBDL?
Investing in CBD Life Sciences Inc. (CBDL) presents significant risks due to its current financial standing and competitive landscape. With a negative profit margin of -905.5% and a negative gross margin of -9.9%, the company's financial viability is questionable. The company's high beta of -3603.52 indicates extreme volatility, making it a speculative investment. Potential growth catalysts include successful product innovation and market expansion, but these are highly uncertain. The company's small size, with only 3 employees, limits its operational capacity. Investors should carefully consider these factors and conduct thorough due diligence before considering an investment in CBDL. The lack of a dividend yield further reduces the attractiveness of the stock for income-seeking investors.
Based on FMP financials and quantitative analysis
CBDL Key Highlights
- Market capitalization of 375K indicates a micro-cap company with limited resources and higher risk.
- P/E ratio of -0.64 reflects negative earnings, suggesting the company is not currently profitable.
- Profit Margin of -905.5% highlights significant operational inefficiencies and challenges in generating profit.
- Gross Margin of -9.9% indicates that the company's cost of goods sold exceeds its revenue, posing a threat to long-term sustainability.
- Beta of -3603.52 suggests the stock is highly volatile and moves inversely to the market, increasing investment risk.
Who Are CBDL's Competitors?
CBDL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CBDL's Key Strengths?
- Focus on cannabidiol (CBD) based organic products.
- Diverse product line including hemp drops, massage oils, and pet products.
- Potential for growth in the expanding CBD market.
What Are CBDL's Weaknesses?
- Negative profit margin of -905.5%.
- Negative gross margin of -9.9%.
- Small number of employees (3), limiting operational capacity.
- High beta of -3603.52 indicating extreme volatility.
What Could Drive CBDL Stock Higher?
- Potential regulatory changes in the CBD market could create new opportunities or challenges.
- Increasing consumer awareness and acceptance of CBD products may drive demand.
- Development and launch of new CBD-infused products targeting specific health conditions.
- Strategic partnerships with established healthcare or retail companies to expand market reach.
What Are the Key Risks for CBDL?
- Financial-distress signal — its Altman Z-Score of -21.38 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-1.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition in the CBD market could erode market share and profitability.
- Regulatory uncertainty and varying state laws create compliance challenges.
- Changes in consumer preferences or negative publicity could reduce demand for CBD products.
- The company's negative profit and gross margins pose a threat to its financial sustainability.
- Limited access to capital may hinder growth and expansion efforts.
What Are the Growth Opportunities for CBDL?
- Expansion of Product Line: CBD Life Sciences can expand its product line to include new CBD-infused products targeting specific health conditions or wellness needs. The market for CBD products is projected to reach $16 billion by 2026, providing ample opportunity for growth. Success depends on effective research and development to create innovative and differentiated products, giving the company a competitive edge.
- Strategic Partnerships: Forming strategic partnerships with established healthcare or retail companies can provide CBD Life Sciences with access to new markets and distribution channels. Collaborating with larger companies can enhance brand visibility and credibility. The timeline for realizing benefits from partnerships depends on the negotiation and implementation process, but strategic alliances can drive growth within the next 1-2 years.
- Online Sales and Marketing: Enhancing its online presence and marketing efforts can help CBD Life Sciences reach a broader customer base. Investing in e-commerce platforms, social media marketing, and search engine optimization can drive online sales. The global e-commerce market is expected to continue growing, offering significant opportunities for CBD Life Sciences to expand its online sales channels and increase revenue.
- International Expansion: Expanding into international markets, particularly in Europe and Asia, can provide CBD Life Sciences with new growth opportunities. The global market for CBD products is expanding, and entering new geographic regions can diversify revenue streams. However, international expansion requires careful consideration of regulatory requirements and cultural differences, which may take 2-3 years to fully implement.
- Focus on Pet Products: The market for CBD pet products is growing rapidly, as pet owners seek natural solutions for their animals' health and wellness. CBD Life Sciences can capitalize on this trend by expanding its line of pet products and marketing them to pet owners. The pet care industry is expected to continue growing, providing a favorable environment for CBD Life Sciences to increase its market share in the pet product segment.
What Opportunities Does CBDL Have?
- Expansion of product line to target specific health conditions.
- Strategic partnerships with established healthcare or retail companies.
- Increased online sales and marketing efforts.
- Expansion into international markets.
What Threats Does CBDL Face?
- Intense competition in the CBD market.
- Regulatory uncertainty and varying state laws.
- Potential changes in consumer preferences.
- Economic downturn affecting consumer spending.
What Are CBDL's Competitive Advantages?
- Proprietary formulations for CBD-infused products.
- Focus on organic and natural ingredients.
- Brand reputation for quality and effectiveness (if established).
What Does CBDL Do?
CBD Life Sciences Inc., based in Scottsdale, Arizona, develops and markets a range of cannabidiol (CBD) based organic products. The company's offerings include hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a line of pet products. Founded to capitalize on the growing market for CBD-infused products, CBD Life Sciences aims to provide consumers with natural and organic alternatives for various health and wellness needs. The company focuses on creating products that leverage the potential therapeutic benefits of CBD. Its product line targets a diverse set of consumer needs, from pain relief and anxiety management to sleep improvement and pet care. CBD Life Sciences operates within the broader healthcare sector, specifically in the specialty and generic drug manufacturing industry, adapting its product offerings to meet evolving consumer preferences and regulatory requirements. Despite its efforts to establish a presence in the CBD market, CBD Life Sciences faces significant challenges, including negative profit margins and intense competition. The company's ability to navigate these challenges and achieve sustainable growth will depend on its success in product innovation, marketing effectiveness, and operational efficiency.
What Products and Services Does CBDL Offer?
- Develops cannabidiol (CBD) based organic products.
- Markets hemp drops for general wellness.
- Offers massage oils for relaxation and therapeutic purposes.
- Provides recovery pain relief creams for muscle and joint pain.
- Sells anxiety and sleep solutions supplements.
- Markets CBD-infused edibles.
- Offers a line of pet products containing CBD.
How Does CBDL Make Money?
- Develops and manufactures CBD-based products.
- Markets products directly to consumers through online channels.
- Generates revenue through the sale of CBD-infused products.
What Industry Does CBDL Operate In?
CBD Life Sciences Inc. operates in the rapidly evolving market for cannabidiol (CBD) products. The industry has experienced substantial growth due to increasing consumer interest in natural health and wellness solutions. However, the market is highly competitive, with numerous companies offering similar products. Regulatory uncertainty and varying state laws add complexity to the business environment. CBD Life Sciences competes with both established pharmaceutical companies and smaller, specialized CBD product manufacturers. The company's success depends on its ability to differentiate its products and navigate the complex regulatory landscape.
Who Are CBDL's Key Customers?
- Individuals seeking natural health and wellness solutions.
- Consumers looking for pain relief and anxiety management products.
- Pet owners seeking CBD products for their pets.
CBD Life Sciences Inc. (CBDL) Valuation Context
Valued at 375K, CBDL is classified as a micro-cap stock. Relative to its peer group, CBDL's quantitative score of 41/100 is below the peer average of 66/100.
CBDL Revenue & Earnings Trend
In Q4 2025, CBDL generated $28K in top-line revenue, marking a sequential increase of 76.6%. The company recorded net income of $32K, with diluted EPS of $0.00. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, CBDL averaged $-0.00 in diluted EPS.
Company Profile
CBD Life Sciences Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Scottsdale, US. The company is led by CEO Lisa Anne Nelson. CBDL has traded publicly since 2009.
ROE -1%Key Financial Metrics
Return on equity for CBD Life Sciences Inc. stands at -1.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.7%, showing how much profit it generates from its asset base. Its free cash flow yield is 12.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 15.12 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
CBD Life Sciences Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -21.38 places it in the distress zone, a signal of elevated financial risk.
CBDL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Focus on cannabidiol (CBD) based organic products.
- Diverse product line including hemp drops, massage oils, and pet products.
- Potential for growth in the expanding CBD market.
- Upcoming: Potential regulatory changes in the CBD market could create new opportunities or challenges.
Bear Case
- Negative profit margin of -905.5%.
- Negative gross margin of -9.9%.
- Small number of employees (3), limiting operational capacity.
- High beta of -3603.52 indicating extreme volatility.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $28,236 | $31,550 | $0.00 |
| Q1 2025 | $15,993 | -$37,567 | $0.00 |
| Q4 2024 | $11,589 | -$341,642 | -$0.0001 |
| Q3 2024 | $15,227 | -$295,671 | -$0.0001 |
Based on FMP financials and quantitative analysis
CBDL Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
CBDL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CBDL.
Price Targets
Wall Street price target analysis for CBDL.
CBDL MoonshotScore
What does this score mean?
The MoonshotScore rates CBDL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lisa Anne Nelson
CEO
Lisa Anne Nelson serves as the CEO of CBD Life Sciences Inc. Her leadership experience involves managing small teams and guiding the company's strategic direction in the competitive CBD market. Nelson's background includes overseeing the development and marketing of CBD-based organic products, focusing on hemp drops, massage oils, and other wellness solutions. Her role requires navigating the regulatory landscape and adapting to evolving consumer preferences within the healthcare sector.
Track Record: Under Lisa Anne Nelson's leadership, CBD Life Sciences Inc. has focused on expanding its product line and reaching new markets. Key milestones include the introduction of CBD-infused pet products and the development of anxiety and sleep solutions supplements. However, the company continues to face challenges related to profitability and market competition, as reflected in its negative profit and gross margins.
CBDL OTC Market Information
The OTC Other tier represents the lowest tier of over-the-counter (OTC) markets, indicating that CBD Life Sciences Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be subject to greater regulatory scrutiny. Investing in companies on the OTC Other tier carries higher risks compared to those listed on major exchanges like NYSE or NASDAQ due to the lack of stringent listing requirements and oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases investment risk.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- Higher potential for fraud or manipulation due to less regulatory oversight.
- OTC Other tier companies may have difficulty raising capital.
- Potential delisting or trading suspension due to non-compliance.
- Verify the company's legal status and registration.
- Review available financial statements and SEC filings.
- Assess the company's management team and their experience.
- Research the company's products and services and their market potential.
- Evaluate the company's competitive position and industry trends.
- Check for any legal or regulatory issues.
- Consult with a financial advisor before investing.
- Company registration with state authorities.
- Existence of a functional website and contact information.
- Publicly available information about the company's products and services.
- Presence of a management team and board of directors.
- Any news coverage or press releases about the company.
CBD Life Sciences Inc. Healthcare Stock: Key Questions Answered
What does CBD Life Sciences Inc. do?
CBD Life Sciences Inc. engages in the development and marketing of cannabidiol (CBD) based organic products. Its product line includes hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a line of pet products. The company focuses on providing natural and organic alternatives for various health and wellness needs, targeting consumers seeking the potential therapeutic benefits of CBD. CBD Life Sciences operates within the specialty and generic drug manufacturing industry.
What do analysts say about CBDL stock?
There is currently no available analyst coverage for CBD Life Sciences Inc. (CBDL) due to its small market capitalization and OTC listing. Key valuation metrics such as price-to-earnings ratio (P/E) and price-to-sales ratio (P/S) are either negative or not meaningful due to the company's current financial performance. Investors should conduct their own thorough analysis and consider the company's financial risks and growth potential before making any investment decisions. The lack of analyst coverage reflects the speculative nature of this investment.
What are the main risks for CBDL?
The main risks for CBD Life Sciences Inc. include its negative profit margin of -905.5% and negative gross margin of -9.9%, indicating significant financial challenges. The company also faces intense competition in the rapidly evolving CBD market, as well as regulatory uncertainty and varying state laws. Its small size, with only 3 employees, limits its operational capacity. Additionally, the company's OTC listing and high beta of -3603.52 indicate increased volatility and investment risk. These factors collectively pose substantial risks to investors.
What are the key factors to evaluate for CBDL?
CBD Life Sciences Inc. (CBDL) holds an AI score of 41/100 (low). Not financial advice.
How frequently does CBDL data refresh on this page?
CBDL prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CBDL's recent stock price performance?
CBD Life Sciences Inc. (CBDL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on cannabidiol (CBD) based organic products. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CBDL overvalued or undervalued right now?
Valuing CBD Life Sciences Inc. (CBDL) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CBDL?
Before investing in CBD Life Sciences Inc. (CBDL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully accurate.
- OTC market investments carry higher risks than exchange-listed stocks.
- The CBD market is subject to regulatory changes and uncertainty.